Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Weaver, Eric A ^a   Rubrum, Adam M ^b   Webby, Richard J ^b   Barry, Michael A ^a,c  

^a MAYO CLINIC   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BASE MISPAIRING; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; UNINDEXED SEQUENCE; VACCINE PRODUCTION; VIRUS ISOLATION; VIRUS PARTICLE; ADENOVIRUS; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA; MOLECULAR GENETICS; ORTHOMYXOVIRUS INFECTION; PHYLOGENY; SEQUENCE ALIGNMENT; VIROLOGY;

ADENOVIRIDAE; MUS; ORTHOMYXOVIRIDAE; SUIDAE;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; SEQUENCE ALIGNMENT;

EID: 79953139384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018314     Document Type: Article

References (40)

1. WHO (2009) Influenza Fact Sheet.
2. Gitelman AK, Kaverin NV, Kharitonenkov IG, Rudneva IA, Zhdanov VM, (1984) Changes in the antigenic specificity of influenza hemagglutinin in the course of adaptation to mice. Virology 134: 230-232.
3. Kilbourne ED, Smith C, Brett I, Pokorny BA, Johansson B, et al. (2002) The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A 99: 10748-10752.
4. Schild GC, Oxford JS, de Jong JC, Webster RG, (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303: 706-709.
5. (1998) Update: influenza activity-United States and worldwide, 1997-98 season, and composition of the 1998-99 influenza vaccine. MMWR Morb Mortal Wkly Rep 47: 280-284.
6. (2001) Update: influenza activity-United States and worldwide, 2000-01 season, and composition of the 2001-02 influenza vaccine. MMWR Morb Mortal Wkly Rep 50: 466-479.
7. (2003) Update: Influenza activity-United States, 2002-03 season. MMWR Morb Mortal Wkly Rep 52: 26-28.
8. (2004) Update: influenza activity-United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep 53: 547-552.
9. Nicholson KG, McNally T, Silverman M, Simons P, Zambon MC, (2003) Influenza-related hospitalizations among young children in Leicestershire. Pediatr Infect Dis J 22: S228-230.
10. Potter CW, Jennings R, Clark A, (1977) The antibody response and immunity to challenge infection induced by whole, inactivated and tween-ether split influenza vaccines. Dev Biol Stand 39: 323-328.
11. Clements ML, Betts RF, Tierney EL, Murphy BR, (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24: 157-160.
12. Muszkat M, Friedman G, Schein MH, Naveh P, Greenbaum E, et al. (2000) Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly. Vaccine 18: 1696-1699.
13. Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, et al. (2003) Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine 21: 1180-1186.
14. Subbarao K, (1999) Influenza vaccines: present and future. Adv Virus Res 54: 349-373.
15. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, et al. (1999) Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259: 256-261.
16. Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD, (2001) A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 20: 158-163.
17. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, et al. (2001) Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 75: 6687-6691.
18. Rimmelzwaan GF, Osterhaust AD, (2001) Influenza vaccines: new developments. Curr Opin Pharmacol 1: 491-496.
19. Webster RG, Askonas BA, (1980) Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 10: 396-401.
20. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 105: 13538-13543.
21. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, et al. (2009) M2e-based universal influenza A vaccine. Vaccine 27: 6280-6283.
22. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80: 1959-1964.
23. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475-481.
24. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, et al. (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25: 2984-2989.
25. Ellenberger DL, Li B, Lupo LD, Owen SM, Nkengasong J, et al. (2002) Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 302: 155-163.
26. Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, et al. (2004) Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 3: S161-168.
27. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
28. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, et al. (2000) Timing the ancestor of the HIV-1 pandemic strains. Science 288: 1789-1796.
29. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, et al. (2003) Consensus and ancestral state HIV vaccines. Science 299: 1515-1518; author reply 1515-1518.
30. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, et al. (2002) Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol 76: 5435-5451.
31. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, et al. (2008) Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 3: e2517.
32. Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, et al. (2008) Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 26: 5128-5134.
33. CDC (2009) H1N1 Flu Vaccine-Why the Delay?.
34. CDC (2009) CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April - November 14, 2009.
35. Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, et al. (2010) Adaptation of pandemic H1N1 influenza viruses in mice. J Virol 84: 8607-8616.
36. Mok H, Palmer DJ, Ng P, Barry MA, (2005) Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79.
37. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, et al. (2006) Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 80: 6745-6756.
38. Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, et al. (2003) Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 7663-7668.
39. Weaver EA, Nehete PN, Buchl SS, Senac JS, Palmer D, et al. (2009) Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 4: e5059.
40. Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, et al. (1997) Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 15: 962-967.